Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Intracranial tumor antigen immune response augmented with local immunotherapy
July 14th, 2006
According to recently published research from the United States, cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy. "Central nervous system (CNS) tumors are thought to be poorly immunogenic. However, whether defective anti-tumor immunity is a consequence of a relative failure of T cell priming versus a deficient effector phase of the anti-tumor immune response is not clear," wrote S. Velicu and colleagues, University of Chicago. "We utilized a well-defined model system of B16 melanoma expressing the model antigen SIY-GFP to evaluate tumor...
Source: Genomics & Genetics Weekly (2006-07-14)
|
